Efficacy of somatostatin and its analogues in prevention of postoperative complications after pancreaticoduodenectomy: A meta-analysis of randomized controlled trials

Pancreas

Volumn 36, Issue 1, 2008, Pages 18-25

  Zeng, Qiqiang ^a   Zhang, Qiyu ^a   Han, Shaoliang ^a   Yu, Zhengping ^a   Zheng, Minghua ^a   Zhou, Mengtao ^a   Bai, Jianling ^b   Jin, Rong ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Octreotide; Pancreaticoduodenectomy; Postoperative complications; Somatostatin; Vapreotide

Indexed keywords

ANGIOPEPTIN; OCTREOTIDE; SOMATOSTATIN; VAPREOTIDE;

ABDOMINAL ABSCESS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MORTALITY; PANCREAS FISTULA; PANCREATICODUODENECTOMY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH EMPTYING; SYSTEMATIC REVIEW;

GASTRIC EMPTYING; HUMANS; LENGTH OF STAY; MEDLINE; OCTREOTIDE; PANCREATIC FISTULA; PANCREATICODUODENECTOMY; POSTOPERATIVE COMPLICATIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SOMATOSTATIN;

EID: 38149043550     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/mpa.0b013e3181343f5d     Document Type: Article

References (26)

1. Yeo CJ, Cameron JL, Sohn TA, et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg. 1997;226(3):248-257.
2. Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg. 2006;10(9):1199-1211.
3. Gouillat C, Chipponi J, Baulieux J, et al. Randomized controlled multicentre trial of somatostatin infusion after pancreaticoduodenectomy. Br J Surg. 2001;88(11):1456-1462.
4. DeOliveira ML, Winter JM, Schafer M, et al. Assessment of complications after pancreatic surgery: a novel grading system applied to 633 patients undergoing pancreaticoduodenectomy. Ann Surg. 2006;244(6):931-937.
5. Klempa I, Schwedes U, Usadel KH. Verhutung von postoperativen pankreatitischen Komplikationen nach Duodenopankreatekomie durch Somatostatin. Chirurgie. 1979;50:427-432.
6. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1-12.
7. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet. 1999;354(9193):1896-1900.
8. Montorsi M, Zago M, Mosca F, et al. Efficacy of octreotide in the prevention of pancreatic fistula after elective pancreatic resections: a prospective, controlled, randomized clinical trial. Surgery. 1995;117(1):26-31.
9. Yeo CJ, Cameron JL, Lillemoe KD, et al. Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy? Results of a prospective randomized placebo-controlled trial. Ann Surg. 2000;232(3):419-429.
10. Lowy AM, Lee JE, Pisters PW, et al. Prospective, randomized trial of octreotide to prevent pancreatic fistula after pancreaticoduodenectomy for malignant disease. Ann Surg. 1997;226(5):632-641.
11. Shan YS, Sy ED, Lin PW. Role of somatostatin in the prevention of pancreatic stump-related morbidity following elective pancreaticoduodenectomy in high-risk patients and elimination of surgeon-related factors: prospective, randomized, controlled trial. World J Surg. 2003;27(6):709-714.
12. Hesse UJ, De Decker C, Houtmeyers P, et al. Prospectively randomized trial using perioperative low dose octreotide to prevent organ related and general complications following pancreatic surgery and pancreatico-jejunostomy. Acta Chir Belg. 2005;105(4):383-387.
13. Suc B, Msika S, Piccinini M, et al. Octreotide in the prevention of intra-abdominal complications following elective pancreatic resection: a prospective, multicenter randomized controlled trial. Arch Surg. 2004;139(3):288-294.
14. Sarr MG. The potent somatostatin analogue vapreotide does not decrease pancreas-specific complications after elective pancreatectomy: a prospective, multicenter, double-blinded, randomized, placebo-controlled trial. J Am Coll Surg. 2003;196(4):556-564.
15. Falconi M, Contro C, Ballabio M, et al. Evaluation of lanreotide effects on human exocrine pancreatic secretion after a single dose: preliminary study. Dig Liver Dis. 2002;34(2):127-132.
16. Shan YS, Sy ED, Tsai ML, et al. Effects of somatostatin prophylaxis after pylorus-preserving pancreaticoduodenectomy: increased delayed gastric emptying and reduced plasma motilin. World J Surg. 2005;29(10):1319-1324.
17. van Berge Henegouwen MI, van Gulik TM, Akkermans LM, et al. The effect of octreotide on gastric emptying at a dosage used to prevent complications after pancreatic surgery: a randomised, placebo controlled study in volunteers. Gut. 1997;41(6):758-762.
18. Topal B, Aerts R, Hendrickx T, et al. Determinants of complications in pancreaticoduodenectomy. Eur J Surg Oncol. 2007;33(4):488-492.
19. Rosenberg L, MacNeil P, Turcotte L. Economic evaluation of the use of octreotide for prevention of complications following pancreatic resection. J Gastrointest Surg. 1999;3(3):225-232.
20. Buchler M, Friess H, Klempa I, et al. Role of octreotide in the prevention of postoperative complications following pancreatic resection. Am J Surg. 1992;163(1):125-130.
21. van Berge Henegouwen MI, Moojen TM, van Gulik TM, et al. Postoperative weight gain after standard Whipple's procedure versus pylorus-preserving pancreatoduodenectomy: the influence of tumour status. Br J Surg. 1998;85(7):922-926.
22. Pederzoli P, Bassi C, Falconi M, et al. Efficacy of octreotide in the prevention of complications of elective pancreatic surgery. Italian Study Group. Br J Surg. 1994;81(2):265-269.
23. Friess H, Beger HG, Sulkowski U, et al. Randomized controlled multicentre study of the prevention of complications by octreotide in patients undergoing surgery for chronic pancreatitis. Br J Surg. 1995;82(9):1270-1273.
24. Connor S, Alexakis N, Garden OJ, et al. Meta-analysis of the value of somatostatin and its analogues in reducing complications associated with pancreatic surgery. Br J Surg. 2005;92(9):1059-1067.
25. Turkcapar AG, Demirer S, Sengul N, et al. The adverse effects of octreotide on the healing of colonic anastomoses in rats. Surg Today. 1998;28(3):279-284.
26. Jamil M, Ahmed U, Sobia H. Role of somatostatin analogues in the management of enterocutaneous fistulae. J Coll Physicians Surg Pak. 2004;14(4):237-240.